Australia markets closed

NeuroSense Therapeutics Ltd. (NRSN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.6900+0.0300 (+1.81%)
At close: 04:00PM EST
1.6400 -0.05 (-2.96%)
After hours: 07:19PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.6600
Open1.6600
Bid1.5300 x 2200
Ask1.6500 x 1000
Day's range1.5500 - 1.7400
52-week range1.0750 - 8.1800
Volume108,744
Avg. volume1,437,124
Market cap19.912M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.6100
Earnings date01 Dec 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.00
  • PR Newswire

    NeuroSense Therapeutics Reports Positive Final Results from Alzheimer's Biomarker Study

    NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced final results from a biomarker study conducted to evaluate the potential of NeuroSense's combination platform therapy for the treatment of Alzheimer's disease (AD). Preliminary results from the study, showed that TDP-43, a novel biomarker, was elevated in AD patients compared to a healthy control group. Based on these encouraging preliminary results,

  • PR Newswire

    NeuroSense Announces Third Quarter 2022 Financial Results and Provides Business Update

    NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its financial results for the quarter ended September 30, 2022 and provided a business update.

  • PR Newswire

    NeuroSense Receives Regulatory Approval to Commence Patient Enrollment in Italy for its Phase 2b Trial in ALS

    NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has received approval from the Italian Medicines Agency (AIFA) to commence patient enrollment in Italy for PARADIGM, the Company's Phase 2b clinical trial of its lead drug candidate PrimeC in the treatment of amyotrophic lateral sclerosis (ALS). PARADIGM is currently enrolling patients in Israel and recently received clearance from the U.S. Food an